Labcorp Holdings Inc. Stock

Equities

LH

US5049221055

Healthcare Facilities & Services

Real-time Estimate Cboe BZX 10:44:45 2024-07-16 am EDT 5-day change 1st Jan Change
212.9 USD +2.59% Intraday chart for Labcorp Holdings Inc. +6.60% -6.51%
Sales 2024 * 12.83B Sales 2025 * 13.47B Capitalization 17.49B
Net income 2024 * 958M Net income 2025 * 1.1B EV / Sales 2024 * 1.73 x
Net Debt 2024 * 4.74B Net Debt 2025 * 4.27B EV / Sales 2025 * 1.62 x
P/E ratio 2024 *
18.3 x
P/E ratio 2025 *
16.1 x
Employees 61,975
Yield 2024 *
1.42%
Yield 2025 *
1.45%
Free-Float 99.65%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.64%
1 week+2.23%
Current month+1.96%
1 month+3.81%
3 months+2.05%
6 months-7.16%
Current year-8.71%
More quotes
1 week
198.96
Extreme 198.96
210.87
1 month
198.07
Extreme 198.07
210.87
Current year
191.97
Extreme 191.97
234.09
1 year
191.97
Extreme 191.97
234.09
3 years
191.97
Extreme 191.97
317.17
5 years
98.02
Extreme 98.02
317.17
10 years
95.61
Extreme 95.61
317.17
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 13-03-31
Director of Finance/CFO 62 14-06-15
Compliance Officer 65 19-01-31
Members of the board TitleAgeSince
Chief Executive Officer 59 13-03-31
Director/Board Member 68 12-12-31
Director/Board Member 66 06-05-16
More insiders
Date Price Change Volume
24-07-16 212.8 +2.55% 75 613
24-07-15 207.5 +0.64% 403,778
24-07-12 206.2 -0.04% 490,238
24-07-11 206.2 +2.93% 709,328
24-07-10 200.4 +0.51% 383,320

Delayed Quote Nyse, July 15, 2024 at 04:00 pm EDT

More quotes
Labcorp Holdings Inc. provides comprehensive laboratory services that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. By leveraging its unparalleled diagnostics and drug development capabilities, the Company provides insights and accelerates innovations to improve health and improve lives. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The Biopharma Laboratory Services segment consists of early development research laboratories and central laboratory services. The Company serves clients in more than 100 countries.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
207.5 USD
Average target price
238 USD
Spread / Average Target
+14.70%
Consensus